Department of Dermatology, Shanghai East Hospital, Tongji University School of Medicine, 150 hao, Jimo Road, Shanghai, 200120, China.
Stem Cell Res Ther. 2024 Oct 8;15(1):353. doi: 10.1186/s13287-024-03959-y.
Concentrated Growth Factor (CGF), rich in CD34 + stem cells, is widely used in treatments for androgenetic alopecia and skin rejuvenation due to its immune-modulating properties. Psoriasis, a chronic inflammatory skin condition, presents significant treatment challenges, particularly for patients who cannot use biologics due to conditions such as cancer and lesions resistant to treatments. The potential of CGF in treating psoriasis is promising, given its broad immunoregulatory effects which confirmed in our previous androgenetic alopecia work.
We evaluated the impact of CGF on IL-17 levels in two contexts: patients treated for androgenetic alopecia and a psoriasis mouse model. Twelve patients received three monthly injections of CGF, with serum IL-17 levels measured before and after treatment. In the psoriasis mouse model, groups were treated with CGF, and outcomes were assessed using the Psoriasis Area and Severity Index (PASI), skin barrier scores, histological analysis, and RNA sequencing. Additionally, in vitro experiments applied CD34 + cells from CGF to keratinocytes to measure levels of TNF-α, IFN-γ, IL-23, and IL-17.
In patients with androgenetic alopecia, three monthly CGF injections resulted in significantly reduced serum IL-17 levels. In the psoriatic mouse model, CGF-treated groups exhibited lower PASI scores and improved skin barrier scores compared to controls. Histological analysis revealed enhanced skin characteristics, while RNA sequencing demonstrated downregulated IL-17 and upregulated CD34 expression, as well as improved expression of barrier-related genes. In vitro, the application of CD34 + cells from CGF to keratinocytes led to a significant reduction in TNF-α, IFN-γ, IL-23, and IL-17 levels, indicating strong anti-inflammatory effects. A clinical case of a psoriasis patient unresponsive to IL-23 therapy (Guselkumab) showed significant improvement following CGF treatment.
These findings indicate that CGF could serve as an effective and versatile treatment for psoriasis, especially for patients who have already undergone biologic therapies but continue to experience resistant lesions.
富含 CD34+干细胞的浓缩生长因子(CGF)因其免疫调节特性,被广泛应用于雄激素性脱发和皮肤年轻化的治疗中。银屑病是一种慢性炎症性皮肤病,治疗具有很大的挑战性,特别是对于那些由于癌症和对治疗有抗性的病变等原因而无法使用生物制剂的患者。鉴于 CGF 在治疗雄激素性脱发方面具有广泛的免疫调节作用,我们在之前的研究中已经证实了这一点,因此 CGF 治疗银屑病具有很大的潜力。
我们评估了 CGF 在两种情况下对 IL-17 水平的影响:接受雄激素性脱发治疗的患者和银屑病小鼠模型。12 名患者接受了三次每月的 CGF 注射,在治疗前后测量血清 IL-17 水平。在银屑病小鼠模型中,用 CGF 治疗各组,并用银屑病面积和严重程度指数(PASI)、皮肤屏障评分、组织学分析和 RNA 测序评估结果。此外,将 CGF 中的 CD34+细胞应用于角质形成细胞,以测量 TNF-α、IFN-γ、IL-23 和 IL-17 的水平。
在雄激素性脱发患者中,三次每月的 CGF 注射可显著降低血清 IL-17 水平。在银屑病小鼠模型中,CGF 治疗组的 PASI 评分较低,皮肤屏障评分较对照组改善。组织学分析显示皮肤特征得到改善,而 RNA 测序显示 IL-17 下调和 CD34 表达上调,以及与屏障相关的基因表达改善。体外,将 CGF 中的 CD34+细胞应用于角质形成细胞可导致 TNF-α、IFN-γ、IL-23 和 IL-17 水平显著降低,表明具有很强的抗炎作用。一名对 IL-23 治疗(古塞库单抗)无反应的银屑病患者的临床病例,在接受 CGF 治疗后显著改善。
这些发现表明,CGF 可作为一种有效且多功能的银屑病治疗方法,特别是对于已经接受生物治疗但仍有耐药病变的患者。